Chemometric models for toxicity classification based on NMR spectra of biofluids

被引:227
作者
Holmes, E
Nicholls, AW
Lindon, JC
Connor, SC
Connelly, JC
Haselden, JN
Damment, SJP
Spraul, M
Neidig, P
Nicholson, JK
机构
[1] Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, London SW7 2AZ, England
[2] SmithKline Beecham Pharmaceut, Dept Safety Assessment, Welwyn Garden City AL6 9AR, Herts, England
[3] SmithKline Beecham Pharmaceut, Dept Analyt Sci, Welwyn Garden City AL6 9AR, Herts, England
[4] Glaxo Wellcome Res & Dev, Preclin Safety Sci Toxicol, Ware SG12 0DP, Herts, England
[5] Bruker Analyt Messtech GmbH, Applicat Dept, D-76287 Rheinstetten, Germany
关键词
D O I
10.1021/tx990210t
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
H-1 NMR spectroscopic and pattern recognition (PR)-based methods were used to investigate the biochemical variability in urine obtained from control rats and from rats treated with a hydrazine (a model hepatotoxin) or HgCl2 (a model renal cortical toxin). The 600 MHz H-1 NMR spectra of urine samples obtained from vehicle- or toxin-treated Han-Wistar (HW) and Sprague-Dawley (SD) rats were acquired, and principal components analysis (PCA) and soft independent modeling of class analogy (SIMCA) analysis were used to investigate the H-1 NMR spectral data. Variation and strain differences in the biochemical composition of control urine samples were assessed. Control urine H-1 NMR spectra obtained from the two rat strains appeared visually similar. However, chemometric analysis of the control urine spectra indicated that HW rat urine contained relatively higher concentrations of lactate, acetate, and taurine and lower concentrations of hippurate than SD rat urine. Having established the extent of biochemical variation in the two populations of control rats, PCA was used to evaluate the metabolic effects of hydrazine and HgCl2 toxicity. Urinary biomarkers of each class of toxicity were elucidated from the PC loadings and included organic acids, amino acids, and sugars in the case of mercury, while levels of taurine, beta-alanine, creatine, and 2-aminoadipate were elevated after hydrazine treatment. SIMCA analysis of the data was used to build predictive models (from a training set of 416 samples) for the classification of toxicity type and strain of rat, and the models were tested using an independent set of urine samples (n = 124). Using models constructed from the first three PCs, 98% of the test samples were correctly classified as originating from control, hydrazine-treated, or HgCl2-treated rats. Furthermore, this method was sensitive enough to predict the correct strain of the control samples for 79% of the data, based upon the class of best fit. Incorporation of these chemometric methods into automated NMR-based metabonomics analysis will enable on-line toxicological assessment of biofluids and will provide a tool for probing the mechanistic basis of organ toxicity.
引用
收藏
页码:471 / 478
页数:8
相关论文
共 25 条
  • [1] ANTHONY ML, 1994, MOL PHARMACOL, V46, P199
  • [2] Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins
    Beckwith-Hall, BM
    Nicholson, JK
    Nicholls, AW
    Foxall, PJD
    Lindon, JC
    Connor, SC
    Abdi, M
    Connelly, J
    Holmes, E
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1998, 11 (04) : 260 - 272
  • [3] Beebe K.R., 1998, CHEMOMETRICS PRACTIC
  • [4] CHEMICAL-EXCHANGE AND PARAMAGNETIC-T2 RELAXATION AGENTS FOR WATER SUPPRESSION IN SPIN-ECHO PROTON NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY OF BIOLOGICAL-FLUIDS
    CONNOR, S
    NICHOLSON, JK
    EVERETT, JR
    [J]. ANALYTICAL CHEMISTRY, 1987, 59 (24) : 2885 - 2891
  • [5] Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive H-1 NMR studies of urine
    Connor, SC
    Hughes, MG
    Moore, G
    Lister, CA
    Smith, SA
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (03) : 336 - 344
  • [6] ElDeredy W, 1997, NMR BIOMED, V10, P99, DOI 10.1002/(SICI)1099-1492(199705)10:3<99::AID-NBM461>3.0.CO
  • [7] 2-#
  • [8] Eriksson L., 1999, INTRO MULTI MEGAVARI
  • [9] GARTLAND KPR, 1989, MOL PHARMACOL, V35, P242
  • [10] HOLMES E, 1992, MOL PHARMACOL, V42, P922